Chances are you already know us
Since we launched our first IVD test kit in 1966 our products have consistently been recognized by the market for their excellence.
We have carried out a number of successful acquisitions of best-in-class IVD companies over the years (e.g. Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010).
This has further reinforced the know-how in our group and bolstered our capacity to innovate, develop, produce and deliver products of only the highest quality.
Product categories:
Products by diseases and disorders:
News & Events
View all news & upcoming events
Healthcare for You.
With our deep involvement in human health, we aim to be a group that contributes to the development of healthcare through trust and innovation.
What we hold dear is the starting point for the creation of a prosperous future.
That is, the health of each and every person.
Because we have been watching over people's health for many decades, we are able to change the future of medical care and create new possibilities in healthcare.
We will continue the challenge to deliver optimal healthcare to each individual.
We will move forward, unceasingly.
Healthcare for You.
For your health, for your future happiness.
A global partner of choice
Today, we sell our products in more than 100 countries worldwide.
We have offices in the United States, Latin America, Europe and Asia, and are supported by an international distribution network and leading OEMs.
Our proven commitment to manufacturing quality has earned us a strong reputation with our direct customers, and global partners at leading diagnostic companies.
Regulatory documents
Browse and download regulatory documents for our broad range of products.
Customer support
Contact our expert teams or international distribution network for product support.
Quality
We are certified for compliance with ISO 13485 and ISO 14001 and are compliant with any local requirements of countries where we sell products (cGMP,…).
Insights
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Aug 26, 2020
An overview of ovarian cancer: the development of biomarkers for early detection
It has been estimated that in 2020, about 21,750 women in the US will receive a new ovarian cancer diagnosis and about 13,940 women will die from this...
Jul 29, 2020
Our own Rebecca Millecamps, Marketing Manager at Fujirebio, was interviewed for the podcast series 'Molecules, microbes and multiomics' about the...
Jun 22, 2020